ClinicalTrials.gg
Active, not recruitingNCT04490915CAHtalystUpdated May 11, 2026Results posted

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

A Phase 3 interventional study of Crinecerfont and Placebo in Congenital Adrenal Hyperplasia, sponsored by Neurocrine Biosciences. Active, not recruiting at 70 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences — 2 open to participants now, 5 under way, 2 of them phase 3. Adrenal Hyperplasia, Congenital · Neurocrine Biosciences.

Enrollment
Largest of 16
182 · median 24
Started
2020
the only one that year
Phase 3
6 of 16
none open now
Registered
11th of 16
by date

Among the 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences, this one has the largest enrollment, is the only one that started in 2020, is one of 6 in phase 3, and was the 11th registered.

Adrenal Hyperplasia, Congenital

101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.

Browse Adrenal Hyperplasia, Congenital studies →

Open to participants now

2 of the 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences, or all of them as a file.
02

Study summary

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency. The study consists of a 24-week randomized, double-blind, placebo-controlled period, followed by 1 year of active treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 20 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).

03

Conditions studied

  • Congenital Adrenal Hyperplasia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be willing and able to adhere to the study procedures, including all requirements at the study center and return for the follow-up visit.
  2. Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency.
  3. Be on a stable regimen.
  4. Participants of must agree to use an acceptable method of during the study.

Exclusion criteria

Exclusion Criteria:

  1. Have a diagnosis of any of the other known forms of classic CAH.
  2. Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic therapy.
  3. Have a unstable medical condition or chronic disease other than CAH.
  4. Have a history of cancer unless considered cured.
  5. Are pregnant.
  6. Have a known history of clinically significant arrhythmia or abnormalities on .
  7. Have a known to any corticotropin releasing hormone receptor antagonists.
  8. Have received any other drug within 30 days before initial screening or plan to use an investigational drug (other than the study drug) during the study.
  9. Have current substance dependence, or current substance (drug) or alcohol abuse.
  10. Have had a blood loss ≥550 mL or donated blood or blood products within 8 weeks prior to the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
182 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo capsule, administered orally, twice daily for 24 weeks, followed by active treatment with crinecerfont for at least 1 year.

    Drug: Crinecerfont · Drug: Placebo

  • Experimental
    Crinecerfont

    Crinecerfont capsule, administered orally, twice daily for 24 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 1 year.

    Drug: Crinecerfont

Interventions

  • CRF type 1 receptor antagonist

    Also known as: NBI-74788, Crenessity

  • DrugPlacebo

    Non-active dosage form

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Glucocorticoid Daily Dose at Week 24

    Least square (LS) mean and standard error (SE) were calculated using analysis of covariance (ANCOVA) model.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in Serum Androstenedione at Week 4

    Time frame: Baseline, Week 4

  2. Number of Participants Who Achieved a Reduction to Physiologic Glucocorticoid Dose While Maintaining Androstenedione Control at Week 24

    Time frame: Week 24

  3. Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 24

    Time frame: Baseline, Week 24

  4. Percent Change From Baseline in Body Weight at Week 24

    Time frame: Baseline, Week 24

  5. Change From Baseline in Percent Total Fat Mass at Week 24

    Time frame: Baseline, Week 24

  6. Change From Baseline in Serum 17-hydroxyprogesterone (17-OHP) at Week 4

    Time frame: Baseline, Week 4

  7. Change From Baseline in Blood Pressure at Week 24

    Time frame: Baseline, Week 24

  8. Change From Baseline in Glucose Tolerance at Week 24

    Time frame: Baseline, Week 24

  9. Change From Baseline in Waist Circumference at Week 24

    Time frame: Baseline, Week 24

  10. Change From Baseline in Menstrual Regularity at Week 24

    Time frame: Baseline, Week 24

  11. Change From Baseline in Testicular Adrenal Rest Tumor (TART) Volume at Week 24

    Time frame: Baseline, Week 24

07

Results

Posted Feb 5, 2025

Participant flow

DB Treatment Period (24 Weeks)
Participant flow — DB Treatment Period (24 Weeks)
MilestonePlaceboCrinecerfont
Started60122
Received at least 1 dose of study drug59122
Completed57117
Not completed35
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up11
Withdrew: Adverse event01
OL Treatment Period (6 Months)
Participant flow — OL Treatment Period (6 Months)
MilestonePlaceboCrinecerfont
Started57117
Received at least 1 dose of study drug57117
Completed2257
Not completed3560
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up01
Withdrew: Adverse event01
Withdrew: Ongoing in the study3458

Outcome measures

PrimaryPercent Change From Baseline in Glucocorticoid Daily Dose at Week 24

Least square (LS) mean and standard error (SE) were calculated using analysis of covariance (ANCOVA) model.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Glucocorticoid Daily Dose at Week 24
percent changePlaceboCrinecerfont
Percent Change From Baseline in Glucocorticoid Daily Dose at Week 24-10.300 ± 3.247-27.322 ± 2.418
Statistical analysis
  • Placebo vs Crinecerfont · ANCOVA · p = <0.0001 · Ls mean difference: -17.022 · 95% CI -23.802 to -10.243LS Mean Difference of Crinecerfont - Placebo
SecondaryChange From Baseline in Serum Androstenedione at Week 4
Time frame:
Baseline, Week 4

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Achieved a Reduction to Physiologic Glucocorticoid Dose While Maintaining Androstenedione Control at Week 24
Time frame:
Week 24

Results for this outcome have not been posted.

SecondaryChange From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 24
Time frame:
Baseline, Week 24

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in Body Weight at Week 24
Time frame:
Baseline, Week 24

Results for this outcome have not been posted.

SecondaryChange From Baseline in Percent Total Fat Mass at Week 24
Time frame:
Baseline, Week 24

Results for this outcome have not been posted.

SecondaryChange From Baseline in Serum 17-hydroxyprogesterone (17-OHP) at Week 4
Time frame:
Baseline, Week 4

Results for this outcome have not been posted.

SecondaryChange From Baseline in Blood Pressure at Week 24
Time frame:
Baseline, Week 24

Results for this outcome have not been posted.

SecondaryChange From Baseline in Glucose Tolerance at Week 24
Time frame:
Baseline, Week 24

Results for this outcome have not been posted.

SecondaryChange From Baseline in Waist Circumference at Week 24
Time frame:
Baseline, Week 24

Results for this outcome have not been posted.

SecondaryChange From Baseline in Menstrual Regularity at Week 24
Time frame:
Baseline, Week 24

Results for this outcome have not been posted.

SecondaryChange From Baseline in Testicular Adrenal Rest Tumor (TART) Volume at Week 24
Time frame:
Baseline, Week 24

Results for this outcome have not been posted.

Adverse events

Collected over Baseline up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Period: Placebo0/60 (0%)0/59 (0%)39/59 (66.1%)
DB Period: Crinecerfont0/122 (0%)4/122 (3.3%)76/122 (62.3%)
Most frequent serious events
Most frequent serious events
EventDB Period: PlaceboDB Period: Crinecerfont
Cholecystitis acuteHepatobiliary disorders0/591/122
Groin abscessInfections and infestations0/591/122
CellulitisInfections and infestations0/591/122
Adrenocortical insufficiency acuteEndocrine disorders0/591/122
PresyncopeNervous system disorders0/591/122
Most frequent other events
Showing 10 of 19
Most frequent other events
EventDB Period: PlaceboDB Period: Crinecerfont
FatigueGeneral disorders9/5930/122
HeadacheNervous system disorders9/5919/122
Coronavirus infectionInfections and infestations5/5917/122
NasopharyngitisInfections and infestations8/596/122
Upper respiratory tract infectionInfections and infestations7/5911/122
PyrexiaGeneral disorders6/597/122
DiarrhoeaGastrointestinal disorders5/5910/122
NauseaGastrointestinal disorders5/5910/122
VomitingGastrointestinal disorders5/596/122
AnxietyPsychiatric disorders5/594/122

Baseline characteristics

Full Analysis Set included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboCrinecerfontTotal
Mean29.8 ± 10.1731.3 ± 9.8230.8 ± 9.93
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCrinecerfontTotal
Female296190
Male316192
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCrinecerfontTotal
Hispanic or Latino8614
Not Hispanic or Latino52116168
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCrinecerfontTotal
American Indian or Alaska Native011
Asian055
Native Hawaiian or Other Pacific Islander000
Black or African American022
White57107164
More than one race112
Unknown or Not Reported268
Daily Glucocorticoid Dose
Daily Glucocorticoid Dose(milligrams (mg)/day)PlaceboCrinecerfontTotal
Mean32.06 ± 32.0632.44 ± 9.2432.31 ± 9.30
Daily Glucocorticoid Dose Adjusted for Body Surface Area
Daily Glucocorticoid Dose Adjusted for Body Surface Area(mg/square meter (m^2)/day)PlaceboCrinecerfontTotal
Mean17.91 ± 5.4517.45 ± 4.5417.60 ± 4.85
08

Study locations

70 sites
  • Neurocrine Clinical Site
    Los Angeles, California 90027, United States
  • Neurocrine Clinical Site
    San Diego, California 92123, United States
  • Neurocrine Clinical Site
    San Francisco, California 94143, United States
  • Neurocrine Clinical Site
    Aurora, Colorado 80045, United States
  • Neurocrine Clinical Site
    Atlanta, Georgia 30329, United States
  • Neurocrine Clinical Site
    Indianapolis, Indiana 46202, United States
  • Neurocrine Clinical Site
    Bethesda, Maryland 20982, United States
  • Neurocrine Clinical Site
    Boston, Massachusetts 02115, United States
  • Neurocrine Clinical Site
    Ann Arbor, Michigan 48109, United States
  • Neurocrine Clinical Site
    Minneapolis, Minnesota 55454, United States
  • Neurocrine Clinical Site
    Rochester, Minnesota 55905, United States
  • Neurocrine Clinical Site
    St Louis, Missouri 63110, United States
  • Neurocrine Clinical Site
    Great Neck, New York 11021, United States
  • Neurocrine Clinical Site
    New York, New York 10029, United States
  • Neurocrine Clinical Site
    Winston-Salem, North Carolina 27157, United States
  • Neurocrine Clinical Site
    Tulsa, Oklahoma 74135, United States
  • Neurocrine Clinical Site
    Philadelphia, Pennsylvania 19104, United States
  • Neurocrine Clinical Site
    Pittsburgh, Pennsylvania 15224, United States
  • Neurocrine Clinical Site
    Dallas, Texas 75390, United States
  • Neurocrine Clinical Site
    Seattle, Washington 98105, United States
  • Neurocrine Clinical Site
    Graz, 8036, Austria
  • Neurocrine Clinical Site
    Vienna, 1090, Austria
  • Neurocrine Clinical Site
    Brussels, 1070, Belgium
  • Neurocrine Clinical Site
    Leuven, 3000, Belgium
  • Neurocrine Clinical Site
    Sofia, 1431, Bulgaria
  • Neurocrine Clinical Site
    Sofia, 1606, Bulgaria
  • Neurocrine Clinical Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Neurocrine Clinical Site
    Hradec Králové, 50005, Czechia
  • Neurocrine Clinical Site
    Angers, 49933, France
  • Neurocrine Clinical Site
    Grenoble, 38700, France
  • Neurocrine Clinical Site
    Le Kremlin-Bicêtre, 94270, France
  • Neurocrine Clinical Site
    Nantes, 44093, France
  • Neurocrine Clinical Site
    Paris, 75651, France
  • Neurocrine Clinical Site
    Paris, 75679, France
  • Neurocrine Clinical Site
    Dresden, 01307, Germany
  • Neurocrine Clinical Site
    Essen, 45147, Germany
  • Neurocrine Clinical Site
    Frankfurt, 60590, Germany
  • Neurocrine Clinical Site
    Leipzig, 04103, Germany
  • Neurocrine Clinical Site
    Munich, 80336, Germany
  • Neurocrine Clinical Site
    Athens, 106 76, Greece
  • Neurocrine Clinical Site
    Athens, 115 27, Greece
  • Neurocrine Clinical Site
    Athens, 11527, Greece
  • Neurocrine Clinical Site
    Thessaloniki, 54642, Greece
  • Neurocrine Clinical Site
    Afula, 1834111, Israel
  • Neurocrine Clinical Site
    Beersheba, 8410101, Israel
  • Neurocrine Clinical Site
    Petah Tikva, 4941480, Israel
  • Neurocrine Clinical Site
    Tel Aviv, 64239, Israel
  • Neurocrine Clinical Site
    Ancona, 60126, Italy
  • Neurocrine Clinical Site
    Bologna, 40138, Italy
  • Neurocrine Clinical Site
    Florence, 50139, Italy
  • Neurocrine Clinical Site
    Messina, 98125, Italy
  • Neurocrine Clinical Site
    Milan, 20132, Italy
  • Neurocrine Clinical Site
    Milan, 20149, Italy
  • Neurocrine Clinical Site
    Naples, 80131, Italy
  • Neurocrine Clinical Site
    Padova, 35128, Italy
  • Neurocrine Clinical Site
    Roma, 00161, Italy
  • Neurocrine Clinical Site
    Leiden, 2333, Netherlands
  • Neurocrine Clinical Site
    Krakow, 31-011, Poland
  • Neurocrine Clinical Site
    Poznan, 60-355, Poland
  • Neurocrine Clinical Site
    Warsaw, 01-809, Poland
  • Neurocrine Clinical Site
    Porto, 4200-319, Portugal
  • Neurocrine Clinical Site
    Belgrade, 11000, Serbia
  • Neurocrine Clinical Site
    Madrid, 28034, Spain
  • Neurocrine Clinical Site
    Seville, 41013, Spain
  • Neurocrine Clinical Site
    Gothenburg, 41345, Sweden
  • Neurocrine Clinical Site
    Stockholm, 17176, Sweden
  • Neurocrine Clinical Site
    Cardiff, CF14 4HH, United Kingdom
  • Neurocrine Clinical Site
    London, WC1B 5EH, United Kingdom
  • Neurocrine Clinical Site
    Manchester, M20 4BX, United Kingdom
  • Neurocrine Clinical Site
    Salford, M6 8HD, United Kingdom
09

References and documents

Publications

  • Auchus RJ, Hamidi O, Pivonello R, Bancos I, Russo G, Witchel SF, Isidori AM, Rodien P, Srirangalingam U, Kiefer FW, Falhammar H, Merke DP, Reisch N, Sarafoglou K, Cutler GB Jr, Sturgeon J, Roberts E, Lin VH, Chan JL, Farber RH; CAHtalyst Adult Trial Investigators. Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia. N Engl J Med. 2024 Aug 8;391(6):504-514. doi: 10.1056/NEJMoa2404656. Epub 2024 Jun 1. PubMed 38828955 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Jul 2023, 31 months.

Results were first posted in Feb 2025, 1 year 6 months after primary completion. A results delay was requested in Jul 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2020
First posted
Jul 29, 2020
StartActual
Dec 16, 2020
Primary completionActual
Jul 19, 2023
CompletionEst.
Aug 2027
Results delay requested
Jul 11, 2024
Results first posted
Feb 5, 2025
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04490915
Responsible party
Sponsor
First posted
Jul 29, 2020
Start date
Dec 16, 2020
Primary completion
Jul 19, 2023
Completion
Aug 2027 (estimated)
Results posted
Feb 5, 2025
Last update
May 11, 2026

Study contacts

Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crinecerfont

Start the discussion